AstraZeneca Leaps Into Nanomedicine With Bind Cancer Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca signs on with Bind to develop a nanotechnology-based, targeted kinase inhibitor that could be used in a number of liquid and solid cancers. For Bind, the news is highly validating as the company’s third deal with a major biopharma in 2013.